undamentalytics Newsletter
Sign in

Apimeds Pharmaceuticals US, Inc. (APUS) stock

Add to watchlist

Add holding +

NYSE: APUS NYSE Pharmaceuticals

Apimeds Pharmaceuticals US, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

The Fundamentalytics view

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Apimeds Pharmaceuticals US, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 213% and a beta of 1.6 against the S&P 500.
  • Short interest rising. Shares sold short rose 606% in a month to 9.1% of tradable shares.

Price chart

  • 1 day-4.0%
  • 1 week-0.2%
  • 1 month-10.2%
  • This year-82.4%
  • 1 year-86.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-60.04

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Leadership
  3. Announcement
  4. Governance
  5. Leadership
  6. Agreement
  7. Announcement
  8. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Apimeds Pharmaceuticals US, Inc. valuation models and calculator

No model value for Apimeds Pharmaceuticals US, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Apimeds Pharmaceuticals US, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.8%: the 10-year Treasury yield (4.9%) plus a beta of 0.86 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no positive revenue in the latest twelve months
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Apimeds Pharmaceuticals US, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Apimeds Pharmaceuticals US, Inc.: too few analysts cover it.

Positioning

Short interest
9.1%
of tradable shares
Days to cover
0.01
at average volume
Short interest, 1 month
+606%
to October 15, 2026
Held by institutions
3%
of shares
Held by insiders
58.7%
of shares

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2026 to date
Return
APUS−82%
Industry peers (median)−12%
S&P 500+11%
Months that ended higher
APUS36%
S&P 50046%
Largest fall from a high during the year
APUS−95%
S&P 500−9%

Worst fall since May 9, 2025: 96% from November 17, 2025 to September 16, 2026. Getting back needed a 2334% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.60 – $38.95
From 52-week high
−92.6%
vs 50-day average
−21.0%
vs 200-day average
−73.3%
Volatility (1 year)
213%
Beta vs S&P 500
1.55

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Apimeds Pharmaceuticals US, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Apimeds Pharmaceuticals US, Inc. in brief

What does Apimeds Pharmaceuticals US, Inc. do?
Apimeds Pharmaceuticals US, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Apimeds Pharmaceuticals US, Inc.'s stock ticker?
Apimeds Pharmaceuticals US, Inc. trades under the ticker APUS on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.